NEW YORK, Jan. 29, 2015 /PRNewswire/ -- Analyst report issued by Small Cap IR. PositiveID Corp. (OTCQB: PSID) based in Delray Beach and Pleasanton, CA Fla. is a developer of biological detection and diagnostics solutions, announced today that it has completed the design of the second-phase (bench-top) prototype, the first major milestone in the development of the Firefly Dx second-phase prototype. With the completion of this design, the Company has begun to build the second-phase prototype of Firefly Dx, a real-time, handheld, polymerase chain reaction (PCR) pathogen detection system, which it expects to complete during the first half of 2015.
So far this year, the stock is down about 22.07%. The stock popped back during October amid the Ebola, where it reached $0.07. Positive ID reported a revenue of $325,000 for Q3 2014, the first revenue generation since its business launching in 2011. The Q4 results should be released soon.
On January 14, 2015, the company announced that it had completed the design of the second-phase (bench-top) prototype - the first major milestone in the development of the Firefly Dx second phase prototype. PositiveID has begun to build the second-phase prototype, which is expected to be completed during the first half of 2015. This would be considered a significant update in term of company operation. Also, the firm had entered into a strategic financing of $4 million that would enabled the company to bring its Firefly technology to field testing and commercialization.
An analyst report which details the current situation, an overview of the company and analyst comments can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
http://bit.ly/---PSID---AnalystReport
Copy and paste to browser may be required.
About Small Cap IR
We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports written by chartered financial analysts (CFA's) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
For more information and services provided beyond this release please use contact information provided below.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapir.com. For any urgent concerns or inquiries please contact us at editor@smallcapir.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Contact: editor@smallcapir.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/positiveid-analyst-report-issued-by-small-cap-ir-biothreat-detection-contender-continues-progress-300027665.html
SOURCE Small Cap IR
